Much effort has been executed in developing and testing the effectiveness and safety of vaccines for SARS-CoV-2 (Coronavirus COVID-19) in the currently ongoing pandemic. One of the vaccines that has been approved on the global market is the AstraZeneca ChA-dOx1 nCov-19 vaccine [1, 2]. Strict documentation of complications and side effects enabled us to gain insight into the potential risks of the vaccine [1, 2]. Since its introduction cases have been reported with complications such as thrombosis, thrombocytopenia and coagulation disorders such as a deviating D-dimer count and abnormalities in the international normalized ratio, partial thromboplastin time or fibrinogen level. Potentially, this resulted in cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis (SVT), as well as arterial thrombosis [3− 6].

With great interest we have read the editorial article entitled ‘COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis.’that was published in the April’s issue of the journal [7]. In this article, the authors propose a stepwise protocol for clinicians aiming to detect the clinical cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) so that adequate therapy can be administered in a timely matter. Regarding SVT in particular, the authors advise to further investigate patients with abdominal symptoms after receiving the AstraZeneca ChAdOx1 nCov-19 vaccine. The associated symptoms that were listed contained: severe abdominal pain, nausea/vomiting, melena or haematochezia and/or persistent high fevers. Although this may be adequate for most cases, we hereby report a case of VITT with SVT that was presented to our emergency department (ED) with a rather mild symptomatology.